Camizestrant
Based on 8 publication(s) in Google Scholar
Camizestrant (AZD-9833) is a potent and orally active estrogen receptor (ER) antagonist. Camizestrant is used for the study of ER+ HER2-advanced breast cancer.
For research use only. We do not sell to patients.
- Purity: 99.32%
- CAS No.: 2222844-89-3
- Formula: C24H28F4N6
- Molecular Weight:476.51
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Breast Cancer Compound Library
HY-L074
-
Nuclear Receptor Compound Library
HY-L126
-
Heterocyclic Compound Library
HY-L138
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Camizestrant
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
-
Others
-
Flow Cytometry
-
Bio/Physico-chemical Assay
Biological Activity
IC50: estrogen receptor (ER)[1]
Camizestrant is extracted from patent US20180111931A1, example 17[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human ESR1 mutant breast cancer patient derived xenograft with CTC174 cells in female NSG mice[1]
-
Dosage:0.8 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg
-
Administration:Oral administration; 30 days; once daily
-
Result:Inhibited tumor growth in a dose-dependent manner.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2222844-89-3
-
Appearance Solid
-
Molecular Weight 476.51
-
Formula C24H28F4N6
-
Color Light yellow to yellow
-
SMILES
FC(F)(F)CN1[C@H](C2=CC=C(NC3CN(CCCF)C3)C=N2)C4=C(C5=C(NN=C5)C=C4)C[C@H]1C
-
Synonyms
AZD-9833
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
NPJ Precis Oncol
Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterations. [Abstract]2025 Nov 7;9(1):343. PMID: 41203797
Camizestrant purchased from MedChemExpress. Usage Cited in: NPJ Precis Oncol. 2025 Nov 7;9(1):343. [Abstract]
Efficacy of increasing concentrations of Camizestrant (10 μM; 6 days) over a backbone of fixed palbociclib and rogaratinib in the ESR1-mutant PDO.
-
EMBO Mol Med
Activated glucocorticoid receptor is an estrogen receptor silencer in ER+ metastatic breast cancer. [Abstract]2025 Nov 19. PMID: 41261233
Camizestrant purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2025 Nov 19. [Abstract]
Immunoblots showing levels of ER, GR and ERK2 (loading control) in MCF-7 D538G cells treated with Dex (700 nM), Fulvestrant (1 μM), Camizestrant (1 μM) or Elacestrant (1 μM) for 72 h.
-
-
-
bioRxiv
Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer Cells. [Abstract]2024 Jun 2:2024.05.28.596307. PMID: 38854123 -
-
-
Camizestrant purchased from MedChemExpress. Usage Cited in: Harvard University. 2023 Mar. 30487357.
UPS-focused CRISPR degradation screen for ERα-eGFP stability in K562-Cas9 cells treated with Camizestrant at 1 μM for 16 h (n=3).
Camizestrant purchased from MedChemExpress. Usage Cited in: Harvard University. 2023 Mar. 30487357.
Flow analysis of ERα-eGFP degradation in K562-Cas9 cells transduced with indicated shRNA and treated with fulvestrant, elacestrant, amcenestrant, Camizestrant, giredestrant at 1 μM, or brilanestrant, AZD9496, LSZ-102 at 5 μM, or estradiol at 1 μM, or ARV-471 at 0.1 μM for 16 h (n = 3). Cells were starved for 48 h prior to compound treatment.
Camizestrant purchased from MedChemExpress. Usage Cited in: Harvard University. 2023 Mar. 30487357.
Luciferase assay results of ERE activation in T47D-Cas9 cells that were treated with DMSO or indicated SERDs (Camizestrant, ect.) at 1 μM for 6 h (n=3). Cells were starved for 48 h prior to compound treatment. ERE activation was normalized using DMSO control.
Solvent & Solubility
DMSO : 100 mg/mL (209.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 7.5 mg/mL (15.74 mM); Clear solution
This protocol yields a clear solution of ≥ 7.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 7.5 mg/mL (15.74 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 7.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0986 mL | 10.4930 mL | 20.9859 mL | 52.4648 mL |
| 5 mM | 0.4197 mL | 2.0986 mL | 4.1972 mL | 10.4930 mL | |
| 10 mM | 0.2099 mL | 1.0493 mL | 2.0986 mL | 5.2465 mL | |
| 15 mM | 0.1399 mL | 0.6995 mL | 1.3991 mL | 3.4977 mL | |
| 20 mM | 0.1049 mL | 0.5246 mL | 1.0493 mL | 2.6232 mL | |
| 25 mM | 0.0839 mL | 0.4197 mL | 0.8394 mL | 2.0986 mL | |
| 30 mM | 0.0700 mL | 0.3498 mL | 0.6995 mL | 1.7488 mL | |
| 40 mM | 0.0525 mL | 0.2623 mL | 0.5246 mL | 1.3116 mL | |
| 50 mM | 0.0420 mL | 0.2099 mL | 0.4197 mL | 1.0493 mL | |
| 60 mM | 0.0350 mL | 0.1749 mL | 0.3498 mL | 0.8744 mL | |
| 80 mM | 0.0262 mL | 0.1312 mL | 0.2623 mL | 0.6558 mL | |
| 100 mM | 0.0210 mL | 0.1049 mL | 0.2099 mL | 0.5246 mL |
Camizestrant Related Classifications
HY-136255 Related Classifications
Powered by Bioz